Dr. Reddy’s Laboratories Limited — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2023, with comparative fiscal years ended March 31, 2022 and March 31, 2021. The source filing is an annual Form 20-F and does not provide a separate 2022 fourth-quarter reporting period; the requested “2022 Q4” period does not match the filing period.
Business context
Dr. Reddy’s is an India-based global pharmaceutical company reporting under IFRS as issued by the IASB. Its principal segments are Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Products include generics, branded generics, biosimilars, over-the-counter products, APIs, intermediates, contract research and manufacturing services, and licensing activities. North America, India, Russia and Europe are key markets.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | Rs.245,879 million | Rs.214,391 million | +14.7% |
| Gross profit | Rs.139,343 million | Rs.113,840 million | +22.4% |
| Gross margin | 56.7% | 53.1% | +3.6 percentage points |
| Operating profit | Rs.57,144 million | Rs.29,476 million | +93.9% |
| Profit before tax | Rs.60,367 million | Rs.32,298 million | +86.9% |
| Net profit | Rs.45,067 million | Rs.23,568 million | +91.2% |
| Net margin | 18.3% | 11.0% | +7.3 percentage points |
| Basic EPS | Rs.271.43 | Rs.142.08 | +91.0% |
- Revenue mix: Global Generics generated Rs.213,768 million, or 87% of total revenue, up 19%. PSAI generated Rs.29,069 million, or 12%, down from Rs.30,740 million. Others generated Rs.3,042 million, or 1%.
- Geographic drivers: North America Global Generics revenue rose 36% to Rs.101,704 million, India rose 17% to Rs.48,932 million, and Europe rose 6% to Rs.17,603 million. Russia revenue rose 2% in rupees to Rs.21,228 million but declined 9% in Russian rouble terms.
- Cash flow: Operating cash inflow was Rs.58,875 million, compared with Rs.28,108 million in FY2022. Investing cash outflow was Rs.41,373 million and financing cash outflow was Rs.26,861 million, resulting in a net cash decrease of Rs.9,359 million.
- Liquidity: Cash and cash equivalents were Rs.5,779 million. Working capital was Rs.121,095 million, including Rs.56,018 million of current investments and Rs.38,180 million of mutual fund investments. Uncommitted bank credit lines totaled Rs.68,516 million.
- Debt: Short-term borrowings were Rs.7,390 million and long-term borrowings, including current and non-current portions, totaled Rs.6,082 million. The principal debt obligations excluding leases totaled Rs.11,190 million, including Rs.3,800 million of debentures due within one year. Lease liabilities were additional.
- Capital spending: Net capital expenditures were Rs.18,784 million. Capital commitments were Rs.8,340 million and capital work-in-progress was approximately Rs.9,956 million. Management expects to fund expansion primarily through operating cash flows, cash and investments, and borrowings as required.
Material changes versus the prior comparable period
- Growth was driven by new product launches, higher volumes, favorable foreign exchange effects and selected divestitures. These benefits were partly offset by approximately 8% price erosion in Global Generics, particularly in North America and Europe.
- Global Generics gross margin increased to 62.1% from 57.6%, primarily due to higher-margin launches, government incentives and favorable currency movements.
- PSAI revenue declined 5.4% and gross margin fell to 16.2% from 22.2%, reflecting lower volumes, price erosion and higher manufacturing overhead as a percentage of sales.
- SG&A increased 9.6% to Rs.68,026 million, but declined to 27.7% of revenue from 29.0%. R&D increased 10.9% to Rs.19,381 million, while its revenue ratio declined to 7.9% from 8.2%.
- Impairment expense fell substantially to Rs.699 million from Rs.7,562 million. FY2023 included Rs.272 million of goodwill impairment and Rs.395 million of intangible-asset impairment, primarily related to Nimbus Health and certain products.
- Net other income increased to Rs.5,907 million from Rs.2,761 million, including Rs.5,638 million of present-valued income from a settlement relating to product and patent litigation.
- The effective tax rate declined to 25% from 27%, primarily because of the geographic mix of earnings and recognition of previously unrecognized deferred tax assets.
- The company acquired the Indian rights to the Cidmus cardiovascular brand for Rs.4,633 million and sold selected non-core Indian brands. It also recorded a Rs.991 million loss on the transfer of its Leiden development center.
Guidance, outlook, commentary and risks
The filing does not provide a specific consolidated revenue, earnings or margin guidance range. Management describes growth priorities as market leadership, operational excellence and patient-focused innovation. PSAI management expects growth from investments in technologies and platforms, including peptides, and from partnership-led expansion. The company continues to develop its “Horizon 2” businesses, including digital platforms, direct-to-consumer channels and nutraceuticals.
- Pipeline: During FY2023, the company filed 12 new U.S. ANDAs. At March 31, 2023, 86 U.S. FDA filings were pending, including 45 Paragraph IV filings, with management believing it was first-to-file on 18. Four biosimilar programs were ongoing.
- Mayne acquisition: The company completed the acquisition of Mayne Pharma’s U.S. generic prescription portfolio on April 6, 2023 for net consideration of U.S.$93 million, including approximately 45 commercial products, 40 approved non-marketed products and four pipeline products.
- Russia and Ukraine: Russia represented 10% of Global Generics revenue and countries of the former Soviet Union and Romania represented another 4%. The company reported higher freight costs and longer supplier lead times but no significant product shortages as of the filing date. Sanctions, currency controls, geopolitical escalation and supply-chain disruption remain material risks.
- Regulatory and quality matters: The U.S. FDA issued a Form 483 with four observations following a May 2023 inspection of Formulations Srikakulam Plant 2 and one observation following a May 2023 inspection of API Hyderabad Plant 1. The company reported that it responded to the observations. Regulatory findings could delay approvals, restrict imports or require costly remediation.
- Litigation and investigations: The company faces patent, pricing, antitrust, product-liability, environmental, tax and regulatory matters. It states that most potential losses are not reasonably estimable and that liabilities beyond recorded provisions are generally not probable. An internal investigation concerning alleged improper payments to healthcare professionals in Ukraine and potentially other countries remains under review by the SEC and DOJ; potential outcomes are not reasonably ascertainable.
- Revenue estimation: North America gross-to-net accruals remain material. At March 31, 2023, North America chargebacks were U.S.$247 million, rebates U.S.$87 million, Medicaid U.S.$13 million and refund liability U.S.$35 million.
- Other risks: Key risks include generic price erosion and customer concentration, manufacturing and supply-chain failures, product quality and regulatory compliance, patent challenges, foreign exchange and commodity-price volatility, cyberattacks, inflation, tax disputes, environmental obligations and impairment of goodwill or intangible assets.
Most important facts for investors to verify
- Confirm that FY2023 results, rather than a separate 2022 fourth-quarter period, are the appropriate comparison for the investment question.
- Assess the sustainability of the 56.7% gross margin and 18.3% net margin after separating new-product launches, foreign exchange benefits, divestiture income and the Rs.5,638 million litigation settlement.
- Review North America pricing trends, chargebacks, rebates, customer concentration and the effect of continued generic competition.
- Evaluate the cash impact of the Mayne acquisition, Rs.8,340 million of capital commitments, the Rs.3,800 million debenture maturity and the proposed Rs.6,661 million dividend.
- Review Note 32 for the latest status and possible exposure from antitrust actions, ranitidine litigation, pricing matters, environmental claims and the SEC/DOJ internal investigation.
- Track remediation and regulatory outcomes related to the May 2023 U.S. FDA Form 483 observations.
- Verify the effect of Russia-Ukraine developments, sanctions, currency movements and supply-chain costs on future reported revenue and cash flow.
- Consider the company’s reliance on foreign currencies, particularly the U.S. dollar, and the sensitivity of earnings and hedging reserves to exchange-rate changes.